Evidence map›Paper›PMID 8601619›Full record

ReviewThe Journal of clinical investigation1996

Transcription syndromes and the role of RNA polymerase II general transcription factors in human disease.

T Aso, A Shilatifard, J W Conaway, R C Conaway

Open access · bronzeAbstract readReview
In one paragraph

Review in The Journal of clinical investigation, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 19 citations in OpenAlex.

  1. The roles of TAF1 in neuroscience and beyond.Royal Society open science · 2024
    Review
  2. Article
  3. Article
  4. Article
  5. ELL2, a new member of an ELL family of RNA polymerase II elongation factors.Proceedings of the National Academy of Sciences of the United States of America · 1997
    Article
  6. In vitro characterization of mutant yeast RNA polymerase II with reduced binding for elongation factor TFIIS.Proceedings of the National Academy of Sciences of the United States of America · 1996
    Article
  7. The RNA polymerase II general elongation factors.Trends in biochemical sciences · 1996
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

T AsoProgram in Molecular and Cell Biology, Oklahoma Medical Research Foundation, Oklahoma City, 73104, USA.
A Shilatifard
J W Conaway
R C Conaway
Oklahoma Medical Research Foundation · US

Funding

BIOCHEMISTRY OF EUKARYOTIC MESSENGER RNA SYNTHESISR37GM041628 · NIGMS · STOWERS INSTITUTE FOR MEDICAL RESEARCH · PI CONAWAY, RONALD C. · 2000 to 2009
$3.8M
BIOCHEMISTRY OF EUKARYOTIC MESSENGER SYNTHESISR01GM041628 · NIGMS · UNIVERSITY OF TEXAS AUSTIN · PI CONAWAY, JOAN W, CONAWAY, RONALD C. · 1989 to 2013
$1.5M
NIGMS NIH HHS GM41628
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Neoplasm ProteinsPeptide Elongation FactorsDNA-Binding ProteinsElonginGene ExpressionGenes, Tumor SuppressorGenetic Diseases, InbornHumansLeukemia, Myeloid, AcutePromoter Regions, GeneticRNA, MessengerRNA Polymerase IITranscriptional Elongation FactorsTranscription FactorsTranscription, Geneticvon Hippel-Lindau DiseaseDNA-Binding ProteinsELL protein, humanElonginNeoplasm ProteinsPeptide Elongation FactorsRNA, MessengerRNA Polymerase IITranscriptional Elongation FactorsTranscription Factors

Identifiers

PMID8601619
PMCPMC507218
OpenAlexW2081248145

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.